Phase I trial of sargramostim/pelareorep therapy in pediatric patients with recurrent or refractory high-grade brain tumors
Why is this work in the frame?
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
The three-model screen
all 1,000 screened works →All three models called this out of scope.
Phase I clinical trial of an oncolytic virus therapy in pediatric brain tumors.
This is a phase I clinical trial of a brain-tumor therapy, not metaresearch.
Phase I clinical trial of oncolytic therapy in pediatric brain tumours.
Abstract
Background: Brain tumors are the leading cause of cancer death for pediatric patients. Pelareorep, an immunomodulatory oncolytic reovirus, has intravenous efficacy in preclinical glioma models when preconditioned with GM-CSF (sargramostim). We report a phase I trial with the primary goal of evaluating the safety of sargramostim/pelareorep in pediatric patients with recurrent or refractory high-grade brain tumors and a secondary goal of characterizing immunologic responses. Methods: The trial was open to pediatric patients with recurrent or refractory high-grade brain tumors (3 + 3 cohort design). Each cycle included 3 days of subcutaneous sargramostim followed by 2 days of intravenous pelareorep. Laboratory studies and imaging were acquired upon recruitment and periodically thereafter. Results: ) were assessed. One patient experienced a dose limiting toxicity of persistent hyponatremia. Common low-grade (1 or 2) adverse events included transient fatigue, hypocalcemia, fever, flu-like symptoms, thrombocytopenia, and leukopenia. High-grade (3 or 4) adverse events included neutropenia, lymphopenia, leukopenia, hypophosphatemia, depressed level of consciousness, and confusion. All patients progressed on therapy after a median of 32.5 days and died a median of 108 days after recruitment. Imaging at progression did not show evidence of pseudoprogression or inflammation. Correlative assays revealed transient but consistent changes in immune cells across patients. Conclusions: Sargramostim/pelareorep was administered to pediatric patients with recurrent or refractory high-grade brain tumors. Hyponatremia was the only dose limiting toxicity (DLT), though maximum tolerated dose (MTD) was not determined.
Stored with the screening record, where it is evidence for the labels above.
The record
- Venue
- Neuro-Oncology Advances
- Topic
- Virus-based gene therapy research
- Field
- Biochemistry, Genetics and Molecular Biology
- Canadian institutions
- Oncolytics Biotech (Canada)
- Funders
- National Cancer InstituteCancer Research UKOncolytics BiotechMayo Clinic
- Keywords
- MedicineLeukopeniaNeutropeniaRefractory (planetary science)Adverse effectGliomaInternal medicineOncolytic virusToxicitySurgeryCancer
- Has abstract in OpenAlex
- yes